



Thank you for selecting our infusion services team to care for your patient. If you are not a PeaceHealth provider, all information listed below is required before we can process orders and schedule your patient for treatment.

**Part A- Patient scheduling and contact information:**

Patient Name (Last, First): \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Patient Contact Information and Phone Number(s): \_\_\_\_\_

Ordering Provider Name (Print): \_\_\_\_\_

Provider Clinic or Service Address: \_\_\_\_\_

Clinic or Service Phone Number: \_\_\_\_\_ Clinic or Service Fax Number: \_\_\_\_\_

Diagnosis (include ICD 10 codes): \_\_\_\_\_

Medication and Service Requested- list J-Code/CPT code if known: \_\_\_\_\_

**Date Service is Requested to Begin:** \_\_\_\_\_ **Date Service is Expected to End:** \_\_\_\_\_

*Order will expire 1 year from date of provider signature unless "date service is expected to end" is earlier.*

**Part B- Insurance and Prior Authorization.** Any non-PeaceHealth provider must obtain prior authorization prior to service. Attach a copy of authorization documentation received from insurance payer when submitting orders.

Insurance (Payer) Company: \_\_\_\_\_

Prior Authorization Number and Conditions: \_\_\_\_\_

Prior Authorization Expiration Date: \_\_\_\_\_

Insurance (Payer) Contact Phone Number: \_\_\_\_\_

**Part C- Elements needed to guide medication therapy are included with request for service:**

- ☐ All orders and instruction (please use the PeaceHealth approved ordering form) are complete and include provider signature AND printed name at the bottom of each order page. Check the boxes of ALL orders you would like to activate.
- ☐ For blood products, PeaceHealth Blood and Transfusion Consent form is signed and dated by the provider and the patient.

**If information is located outside of PeaceHealth's electronic medical record system attach the following:**

- ☐ A list of current medications reconciled by patient provider is available and includes a list of known allergies.
- ☐ Recent progress notes from ordering provider.
- ☐ A copy of relevant laboratory results and other appropriate supporting documentation.

**IMPORTANT MESSAGE TO PROVIDERS:** To reduce delays in treatment and phone calls to your office you may participate in the PHMC formulary process by signing this document. A clinical pharmacist will adjust orders according to PHMC approved policies and procedures.

*I agree to utilize PHMC policies & procedures that have been reviewed by the Pharmacy & Therapeutics Committee and authorized by the Medical Executive Committee of PHMC. This agreement will be issued for the duration of active orders contained within this treatment plan.*

**PROVIDER SIGNATURE:** \_\_\_\_\_ **DATE:** \_\_\_\_\_ **TIME:** \_\_\_\_\_

**FAX completed service request and completed orders to: PHMC OP Infusion and Nursing Services 541-902-1649**



## Darbepoetin (Aranesp) Outpatient Infusion Therapy Plan

All Pre-Selected Boxed Orders Are Initiated by Default Unless Crossed Out by Practitioner. All Boxed Orders Require Practitioner Check to be Initiated.

Heading	Content														
<b>For Admission to Service</b>	<b>Provider Instruction</b> – Please address the following: <ol style="list-style-type: none"> <li>1. Correct preexisting iron, B12 and/or folate deficiencies prior to therapy.</li> <li>2. Provider has screened patient for uncontrolled hypertension, seizures, heart failure, coronary heart disease and stroke prior to initiating therapy.</li> <li>3. Provide patient with the FDA approved medication guide for darbepoetin (Aranesp).</li> </ol>														
<b>Supportive Care</b>	<p><input checked="" type="checkbox"/> <b>Goal of treatment</b> – Hemoglobin level of 10-11 g/dL. Hemoglobin must be below 10 g/dL on initiation</p> <p><b>Choose one of the following (A-C):</b></p> <p>A. <b>Initiation orders for patients with CKD not on dialysis:</b></p> <p><input type="checkbox"/> Darbepoetin alpha-polysorbate (Aranesp) injection 0.45 mcg/kg subcutaneous every <b>2 weeks</b>.</p> <p><input type="checkbox"/> Darbepoetin alpha-polysorbate (Aranesp) injection 0.45 mcg/kg subcutaneous every <b>4 weeks</b>.</p> <p>B. <b>Maintenance orders to continue current dose (renewal of expired orders):</b></p> <p><input type="checkbox"/> Continue darbepoetin alpha-polysorbate (Aranesp) subcutaneous injection at current dose</p> <p>C. <b>Other Indications:</b></p> <p><input type="checkbox"/> Darbepoetin alpha-polysorbate (Aranesp) injection _____ (indicate dose) subcutaneous every _____ (indicate frequency)</p> <p><b>Additional order instruction:</b></p> <p><input checked="" type="checkbox"/> Dose of darbepoetin (Aranesp) may be rounded to the nearest manufacturer's unit of use syringe.</p> <p><input checked="" type="checkbox"/> Pharmacist to adjust dose to maintain therapeutic goal using the following dosing guidelines:</p> <table border="1"> <thead> <tr> <th>Chronic Renal Failure</th><th>Dose Titration</th></tr> </thead> <tbody> <tr> <td>Hgb concentration of 10-11 g/dL (inclusive)</td><td>Therapeutic goal</td></tr> <tr> <td>Hgb increase is less than 1 g/dL after 4 weeks of therapy and iron stores are adequate</td><td>Increase darbepoetin dose up to 25%; do not increase dose more frequently than every 4 weeks</td></tr> <tr> <td>Hgb increase is greater than or equal to 1 g/dL in a 2-week period, or greater than 2 g/dL in a 4-week period</td><td>Reduce darbepoetin dose by 25% to 50%</td></tr> <tr> <td>If Hgb is increasing and approaching 11 g/dL</td><td>Reduce darbepoetin dose by as much as 25%</td></tr> <tr> <td>Hgb is greater than 11 g/dL</td><td>Hold darbepoetin dose until Hgb drops to 11 g/dL. Restart darbepoetin at 75 % of the previous dose</td></tr> <tr> <td>If patient dose not attain target Hgb range 10-11 g/dL within 12 weeks</td><td>Do not continue to increase darbepoetin dose; may require reassessment for other causes of anemia; notify provider for reassessment.</td></tr> </tbody> </table>	Chronic Renal Failure	Dose Titration	Hgb concentration of 10-11 g/dL (inclusive)	Therapeutic goal	Hgb increase is less than 1 g/dL after 4 weeks of therapy and iron stores are adequate	Increase darbepoetin dose up to 25%; do not increase dose more frequently than every 4 weeks	Hgb increase is greater than or equal to 1 g/dL in a 2-week period, or greater than 2 g/dL in a 4-week period	Reduce darbepoetin dose by 25% to 50%	If Hgb is increasing and approaching 11 g/dL	Reduce darbepoetin dose by as much as 25%	Hgb is greater than 11 g/dL	Hold darbepoetin dose until Hgb drops to 11 g/dL. Restart darbepoetin at 75 % of the previous dose	If patient dose not attain target Hgb range 10-11 g/dL within 12 weeks	Do not continue to increase darbepoetin dose; may require reassessment for other causes of anemia; notify provider for reassessment.
Chronic Renal Failure	Dose Titration														
Hgb concentration of 10-11 g/dL (inclusive)	Therapeutic goal														
Hgb increase is less than 1 g/dL after 4 weeks of therapy and iron stores are adequate	Increase darbepoetin dose up to 25%; do not increase dose more frequently than every 4 weeks														
Hgb increase is greater than or equal to 1 g/dL in a 2-week period, or greater than 2 g/dL in a 4-week period	Reduce darbepoetin dose by 25% to 50%														
If Hgb is increasing and approaching 11 g/dL	Reduce darbepoetin dose by as much as 25%														
Hgb is greater than 11 g/dL	Hold darbepoetin dose until Hgb drops to 11 g/dL. Restart darbepoetin at 75 % of the previous dose														
If patient dose not attain target Hgb range 10-11 g/dL within 12 weeks	Do not continue to increase darbepoetin dose; may require reassessment for other causes of anemia; notify provider for reassessment.														
<b>Nursing Orders</b>	<p><input checked="" type="checkbox"/> Hold if hemoglobin exceeds 11 g/dL.</p> <p><input checked="" type="checkbox"/> Patients receiving concurrent treatment with iron sucrose (Venofer) and/or vitamin B12 cannot receive an erythropoiesis stimulating agent treatment on the same day.</p> <p><input checked="" type="checkbox"/> Hold and contact provider if blood pressure is greater than 160/90 mmHg.</p>														
<b>Labs</b>	<p><input checked="" type="checkbox"/> Hemoglobin and hematocrit once prior to beginning treatment and every 7 days for weekly dosing, every 14 days for every 2-week dosing, or every 28 days for every 4-week dosing.</p> <p><input type="checkbox"/> Iron Deficiency Panel once prior to beginning treatment and every 84 days</p> <p><input checked="" type="checkbox"/> Treatment lab instructions – Provider approves to release and draw labs 2 days pre and post this planned treatment date.</p>														

**Practitioner Signature:** \_\_\_\_\_ **Date of Order:** \_\_\_\_\_ **Time:** \_\_\_\_\_

Final page of orders must include signature of the ordering practitioner, date, and time.



## Darbepoetin (Aranesp) Outpatient Infusion Therapy Plan

All Pre-Selected Boxed Orders Are Initiated by Default Unless Crossed Out by Practitioner. All Boxed Orders Require Practitioner Check to be Initiated.

Heading	Content
Referral	<input checked="" type="checkbox"/> Ambulatory referral to OP Infusion Services
PHMC Outpatient Infusion Contact Information	<b>PROVIDER – PLEASE SIGN, DATE AND TIME ORDERS AND RETURN TO:</b> <b>PeaceHealth Peace Harbor Medical Center Outpatient Infusion Services Department</b> 400 Ninth Street Florence, OR 97439 Contact Phone: 541-902-6019 and FAX <b>541-902-1649</b>
Authorization by Verbal or Telephone Order	Person giving verbal or telephone order: _____ Person receiving verbal or telephone order: _____ <input type="checkbox"/> Check to indicate verbal or telephone orders have been read back to confirm accuracy

**Practitioner Signature:** \_\_\_\_\_ **Date of Order:** \_\_\_\_\_ **Time:** \_\_\_\_\_

*Final page of orders must include signature of the ordering practitioner, date, and time.*